Royal Bank of Canada
CRNX icon

Royal Bank of Canada’s Crinetics Pharmaceuticals CRNX Stock Holding History

Royal Bank of Canada’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.81M Buy
49,778
+2,483
+5% +$111K ﹤0.01% 3168
2025
Q4 		$2.2M Sell
47,295
-123,200
-72% -$5.48M ﹤0.01% 3068
2025
Q3 		$7.1M Sell
170,495
-1,984
-1% -$63.4K ﹤0.01% 2402
2025
Q2 		$4.96M Buy
172,479
+145,743
+545% +$4.5M ﹤0.01% 2573
2025
Q1 		$897K Sell
26,736
-2,544
-9% -$95K ﹤0.01% 3562
2024
Q4 		$1.5M Sell
29,280
-5,803
-17% -$325K ﹤0.01% 3232
2024
Q3 		$1.79M Buy
35,083
+3,417
+11% +$176K ﹤0.01% 3073
2024
Q2 		$1.42M Buy
31,666
+6,641
+27% +$307K ﹤0.01% 3169
2024
Q1 		$1.17M Buy
25,025
+4,010
+19% +$157K ﹤0.01% 3329
2023
Q4 		$749K Buy
21,015
+10,211
+95% +$313K ﹤0.01% 3898
2023
Q3 		$321K Buy
10,804
+5,209
+93% +$107K ﹤0.01% 4390
2023
Q2 		$100K Buy
5,595
+2,201
+65% +$43.9K ﹤0.01% 5337
2023
Q1 		$54K Sell
3,394
-3,496
-51% -$64.7K ﹤0.01% 5577
2022
Q4 		$126K Buy
6,890
+5,883
+584% +$104K ﹤0.01% 5278
2022
Q3 		$20K Buy
1,007
+345
+52% +$7.04K ﹤0.01% 6133
2022
Q2 		$13K Sell
662
-2,426
-79% -$48.4K ﹤0.01% 6267
2022
Q1 		$68K Sell
3,088
-6,735
-69% -$136K ﹤0.01% 5883
2021
Q4 		$279K Buy
9,823
+6,546
+200% +$161K ﹤0.01% 5010
2021
Q3 		$69K Buy
3,277
+380
+13% +$7.95K ﹤0.01% 5963
2021
Q2 		$55K Buy
2,897
+1,111
+62% +$19.5K ﹤0.01% 5969
2021
Q1 		$27K Buy
1,786
+1,219
+215% +$18.9K ﹤0.01% 6246
2020
Q4 		$8K Buy
567
+530
+1,432% +$7.38K ﹤0.01% 6469
2020
Q3 		$1K Sell
37
-686
-95% -$10.5K ﹤0.01% 6404
2020
Q2 		$12K Buy
723
+447
+162% +$7.62K ﹤0.01% 5765
2020
Q1 		$4K Sell
276
-206
-43% -$4.22K ﹤0.01% 6103
2019
Q4 		$12K Buy
482
+67
+16% +$1.28K ﹤0.01% 6068
2019
Q3 		$6K Hold
415
– – ﹤0.01% 5942
2019
Q2 		$10K Hold
415
– – ﹤0.01% 6019
2019
Q1 		$9K Buy
415
+385
+1,283% +$9.46K ﹤0.01% 6029
2018
Q4 		$1K Sell
30
-298
-91% -$8.39K ﹤0.01% 6554
2018
Q3 		$9K Buy
+328
New +$9.74K ﹤0.01% 6022

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Royal Bank of Canada's CRNX Position: Q1 2026 in Review

Royal Bank of Canada increased its Crinetics Pharmaceuticals (CRNX) stake by 5.3% in Q1 2026, buying an estimated $111K and bringing the position to 49,778 shares worth $1.81M. The position accounts for ﹤0.01% of the portfolio, ranked #3168.

Royal Bank of Canada first reported a position in CRNX in Q3 2018 and has held it in 31 quarters since. The position peaked at $7.1M in Q3 2025. 243 funds tracked by Wall St. Rank hold CRNX as of Q1 2026.

  • Royal Bank of Canada held 49,778 shares of Crinetics Pharmaceuticals worth $1.81M as of Q1 2026.
  • Royal Bank of Canada bought 2,483 Crinetics Pharmaceuticals shares in Q1 2026, an estimated $111K.
  • Crinetics Pharmaceuticals made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #3168 holding.
  • Royal Bank of Canada first reported a position in Crinetics Pharmaceuticals in Q3 2018 and has held it in 31 quarters since.
  • Royal Bank of Canada's Crinetics Pharmaceuticals position peaked at $7.1M in Q3 2025.
  • 243 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.